28.8% [p≤0.05] vs 13.0%). Secondary endpoints at M3 for tofacitinib 5 mg and 10 mg respectively were: ACR50 response, 29.8% (p≤0.05), 28.0% (p≤0.05); ACR70 response, 16.8% (not significant [NS]), 14.4% (NS); ≥75% improvement of PASI in pts with baseline BSA ≥3% and PASI >0, 21.3% (NS), 43.2% (p<0.0001); LEI and DSS in pts with baseline score >0: LEI, -1.3 (p≤0.05) and -1.3 (p≤0.05) (least squares mean [LSM]); DSS, -5.2 (p≤0.05) and -5.4 (p≤0.05) (LSM). Effects were maintained to M6. Frequency of serious AEs and discontinuations due to AEs was low and similar across treatment groups ( Fig  1E) . The most common AEs were upper respiratory tract infection (5.3-10.8%), nasopharyngitis (1.5-10.7%) and headache (4.5-9.1%).
THURSDAY, 15 JUNE 2017
Immunogenicity of biologics; myth or reality? Background: SB5 has been developed as a biosimilar of reference adalimumab (ADL). The 24-week efficacy and safety results comparing SB5 and ADL were reported previously.
OP0203 IMPACT OF ADALIMUMAB SERUM CONCENTRATION ON EFFICACY AND ASSOCIATION BETWEEN ANTI-DRUG ANTIBODIES AND SERUM CONCENTRATION: 24 WEEK RESULTS FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
1 Here we report results of subgroup analyses of efficacy by adalimumab serum trough concentration (C trough ) and association between anti-drug antibodies (ADA) and C trough . Objectives: To investigate the impact of C trough on efficacy and the association between ADA and C trough in patients with rheumatoid arthritis (RA) treated with SB5 or ADL. Methods: Patients with moderate to severe RA despite methotrexate treatment were randomly assigned to receive 40 mg of either SB5 or ADL administered subcutaneously every other week up to week 24. Blood samples were taken prior to study drug administration at weeks 0, 4, 8, 12, 16, and 24 to measure C trough . The optimal C trough cut-off point of adalimumab for good EULAR response at week 24 is reported to be 1.274 μg/mL.
2 Efficacy and immunogenicity were analysed in patients with C trough <1.274 μg/mL and ≥1.274 μg/mL. Results: C trough was measured in 178 patients each from SB5 and ADL group. The post-dose mean C trough was comparable up to week 24 for SB5 (range: 3.850 to 6.761 μg/mL) and ADL (range: 3.892 to 6.773 μg/mL). Generally, efficacy was higher in patients with C trough ≥1.274 μg/mL for both SB5 and ADL but it was comparable between SB5 and ADL regardless of C trough level. At week 24, the proportion of patients achieving good EULAR response, remission or low disease activity based on DAS28 was higher in patients with C trough ≥1.274 μg/mL than in those with C trough <1.274 μg/mL for both treatment groups (Figure) . Other efficacy parameters, including ACR responses, DAS28, simplified disease activity index, and clinical disease activity index, showed similar results. C trough was higher for patients without detectable ADA, compared to those with ADA. Among patients with ADA, the proportion of patients with C trough ≥1.274 μg/mL was 58.0% (29/50) for SB5 and 52.1% (25/48) for ADL. Among patients without detectable ADA, the proportion of patients with C trough ≥1.274 μg/mL was 100.0% (121/121) for SB5 and 97.4% (114/117) for ADL.
